Venus Medtech (Hangzhou) (HKSE:02500) Price-to-Tangible-Book : 1.68 (As of May. 25, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Venus Medtech (Hangzhou) Price-to-Tangible-Book?

As of today (2024-05-25), Venus Medtech (Hangzhou)'s share price is HK$5.62. Venus Medtech (Hangzhou)'s Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was HK$3.34. Hence, Venus Medtech (Hangzhou)'s Price to Tangible Book Ratio of today is 1.68.

The historical rank and industry rank for Venus Medtech (Hangzhou)'s Price-to-Tangible-Book or its related term are showing as below:

HKSE:02500' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.68 Med: 3.21 Max: 9.16
Current: 1.68

During the past 7 years, Venus Medtech (Hangzhou)'s highest Price to Tangible Book Ratio was 9.16. The lowest was 1.68. And the median was 3.21.

HKSE:02500's Price-to-Tangible-Book is ranked better than
84.5% of 703 companies
in the Medical Devices & Instruments industry
Industry Median: 2.7 vs HKSE:02500: 1.68

A closely related ratio is called PB Ratio. As of today, Venus Medtech (Hangzhou)'s share price is HK$5.62. Venus Medtech (Hangzhou)'s Book Value per Sharefor the quarter that ended in Dec. 2023 was HK$7.24. Hence, Venus Medtech (Hangzhou)'s P/B Ratio of today is 0.78.

Venus Medtech (Hangzhou) Price-to-Tangible-Book Historical Data

The historical data trend for Venus Medtech (Hangzhou)'s Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Venus Medtech (Hangzhou) Price-to-Tangible-Book Chart

Venus Medtech (Hangzhou) Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

5.76

9.16

2.87

3.21

1.68

Venus Medtech (Hangzhou) Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial							2.87	3.27	3.21	1.73	1.68

Competitive Comparison of Venus Medtech (Hangzhou)'s Price-to-Tangible-Book

For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Venus Medtech (Hangzhou)'s Price-to-Tangible-Book Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Venus Medtech (Hangzhou)'s Price-to-Tangible-Book falls into.

Venus Medtech (Hangzhou) Price-to-Tangible-Book Calculation

Venus Medtech (Hangzhou)'s price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	5.62	/	3.336
	=	1.68

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Venus Medtech (Hangzhou) Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Venus Medtech (Hangzhou)'s Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Venus Medtech (Hangzhou) (HKSE:02500) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Venus Medtech (Hangzhou) Inc (HKSE:02500) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

VMTHF:USA

Address

No. 88, Jiangling Road, Room 311, 3rd Floor, Block 2, Binjiang District, Hangzhou, CHN, 310051

Website

https://www.venusmedtech.com

Venus Medtech (Hangzhou) Inc is engaged in the development and commercialization of transcatheter solutions for structural heart diseases. It has two TAVR products on the market, namely VenusA-Valve, and VenusA-Plus. VenusA-Valve is its first-generation TAVR device, which is used to treat severe Aortic Stenosis (AS) using a transcatheter approach. VenusA-Plus is an upgraded product of VenusA-Valve. Geographically all of the revenue is derived from Mainland China.

Executives

Zeng Min Frank	2201 Interest of corporation controlled by you
Zi Zhenjun	2201 Interest of corporation controlled by you
Ming Zhi Investments (bvi) Limited	2101 Beneficial owner
Ming Zhi Investments Limited	2201 Interest of corporation controlled by you
Qiming Venture Partners Iii, L.p.	2201 Interest of corporation controlled by you
Qiming Corporate Gp Iii, Ltd.	2201 Interest of corporation controlled by you
Qiming Gp Iii, L.p.	2201 Interest of corporation controlled by you
Dcp Capital Partners, L.p.	2201 Interest of corporation controlled by you
Dcp General Partner, Ltd	2201 Interest of corporation controlled by you
Dcp, Ltd.	2201 Interest of corporation controlled by you
Liu Haifeng David	2201 Interest of corporation controlled by you
Muheng Capital Partners (hong Kong) Limited	2101 Beneficial owner
Red Giant Limited	2201 Interest of corporation controlled by you
Wolhardt Julian Juul	2201 Interest of corporation controlled by you
Horizon Binjiang Llc	2101 Beneficial owner

Venus Medtech (Hangzhou) (HKSE:02500) Headlines

No Headlines